Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Appropriate specifications at the IND stage

J Geigert1

  • 1Quality, IDEC Pharmaceuticals Corporation, San Diego, CA, USA.

Developments in Biological Standardization
|January 1, 1997
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Appropriate specifications at the IND stage.

PDA journal of pharmaceutical science and technology·1997
Same author

Development and shelf-life determination of recombinant human granulocyte--macrophage colony-stimulating factor (LEUKINE, GM-CSF).

Pharmaceutical biotechnology·1996
Same author

Role of quality control in validation of biopharmaceutical processes: case example of clean-in-place (CIP) procedure for a bioreactor.

PDA journal of pharmaceutical science and technology·1994
Same author

Development and shelf-life determination of recombinant interleukin-2 (proleukin).

Pharmaceutical biotechnology·1993
Same author

Overview of the stability and handling of recombinant protein drugs.

Journal of parenteral science and technology : a publication of the Parenteral Drug Association·1989
Same author

The long-term stability of recombinant (serine-17) human interferon-beta.

Journal of interferon research·1988

Setting early-stage biopharmaceutical product specifications requires careful consideration of available data. This discussion explores practical approaches to establishing scientifically sound specifications during Investigational New Drug (IND) trials.

Area of Science:

  • Biopharmaceutical Development
  • Regulatory Science
  • Quality Control

Background:

  • Biopharmaceutical product specifications must be scientifically sound and appropriate.
  • Early clinical development (Investigational New Drug - IND trials) presents challenges in establishing robust specifications due to limited data.
  • Industry practices may lead to excessive testing and pressure for unrealistic early specifications.

Purpose of the Study:

  • To discuss practical strategies for setting product specifications for biopharmaceuticals at the IND stage.
  • To address the challenges of data limitations and regulatory pressures in early-stage specification setting.
  • To propose a balanced approach to specification setting that avoids premature or overly stringent requirements.

Main Methods:

Related Experiment Videos

  • Review of current industry practices and challenges in setting biopharmaceutical specifications.
  • Discussion of the implications of data availability during early clinical development.
  • Analysis of the influence of regulatory expectations and corporate culture on specification setting.

    • Main Results:

    • Limited data at the IND stage complicates the establishment of scientifically sound specifications.
    • An overemphasis on testing and a "checklist" approach can lead to unnecessary complexity.
    • Setting overly tight specifications early can create future challenges in justification for adjustments.

    Conclusions:

    • Practical product specifications for biopharmaceuticals should be established with consideration for data evolution.
    • A phased approach to specification setting, informed by accumulating data, is recommended.
    • Balancing scientific rigor with practical considerations is crucial for successful early-stage biopharmaceutical development.